ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
about
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal diseaseA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDInnovations in preclinical biology: ex vivo engineering of a human kidney tissue microperfusion systemLow-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.Warfarin dosing in patients with impaired kidney functionEffects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsCYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobioticsSignificant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?Current understanding of drug disposition in kidney disease.Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?Renohepatic crosstalk: does acute kidney injury cause liver dysfunction?Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Consequences of renal failure on non-renal clearance of drugs.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Effect of Disease Pathologies on Transporter Expression and Function.Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal diseaseSystematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.
P2860
Q24613855-F440B899-4EB2-4497-8C5D-764AD45BE4F3Q28087621-36E950DA-166C-4219-8B73-56263E2FEE48Q33644245-6037DEA4-BC50-4E48-AD6F-70557534DEDEQ34005232-67F97FB1-C8F2-422D-9942-DE032878FB70Q34185982-7A548C4A-E2FC-45F4-8E9C-BF41FD6203D9Q34238435-CD05B754-8C7D-40D9-9723-799E3EDCCCAEQ34726696-D6EEA400-93D9-4626-81F0-A87FA5B223DEQ35795744-453D2C56-2FAC-4CC9-91B9-F54C5157B6D2Q36410123-6C4322A3-9BAA-4865-9F0C-E99AC87F69FAQ36634909-FF08AC13-3AC0-4F5F-9A72-76843CCA848DQ36634986-F05FD2BF-8BC6-4855-8C8E-4E7AEDF1AFDDQ37076544-413F07A4-53DE-40CF-80FC-6E91194879C1Q37391009-2F23751A-A354-4B45-A1DF-8369AF7273C7Q37622756-787164E0-29F7-4FA1-AAD5-3917271FB086Q37733572-518FE51E-3297-49E1-97CC-BFD2A1D21E33Q37974644-A5CD9286-C7D5-4E89-B147-4BD044A2BB64Q38048245-47D09C00-3BC7-46A1-8282-08350BF5C3E7Q38107784-2A28E2E5-7B20-4104-A944-4BF7DDCA4AFBQ38153196-955C5475-AA42-4BE2-A368-16D484670C99Q38214827-A3811FC2-1392-45CD-8FC4-D9C67E4F79E5Q38222867-CC5DAFA2-73A1-46F4-9163-A1E03EB19E02Q38888360-E82CE341-2D9F-46A2-9AE4-7BF9230A306AQ38922421-31B64268-E288-4CB4-97D7-814BDEA91F2EQ39107147-CD13C232-2073-4B2A-9585-610DB6956E27Q40072776-DD6B10B4-937E-425B-A90E-E90FBA23F723Q42552831-DC296416-AA4B-49EC-BBFD-14EBE6ED84CFQ43488121-D2748301-7985-47F2-82AB-807B63C9E3D5Q46675919-C201B224-CC8A-4327-8C7E-F441EFB5655DQ47303894-4D18B1C0-4241-4080-A1A9-AE84C2124DF9Q47925309-D58C26F4-1C6F-41FF-A731-C911CB501776Q48150663-1770D82A-B821-4D9B-BA83-A186A77B2001Q48295034-74C6358E-D60D-4685-8112-D1CFD3383DD0Q50108575-4B7D2799-44C2-4727-B250-38D9F1FF3183Q50924422-7A5A5139-6A0D-41FD-BC81-46C9339CDD81Q53838798-2BC32115-2447-4584-8575-EC5587D43F75
P2860
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@en
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@nl
type
label
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@en
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@nl
prefLabel
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@en
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@nl
P2093
P2860
P356
P1476
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
@en
P2093
Francois A Leblond
Hooman Sadr
Jonathan Himmelfarb
Judith Naud
Thomas D Nolin
Vincent Pichette
P2860
P304
P356
10.1681/ASN.2009010082
P577
2009-08-20T00:00:00Z